Research on Hybrid Operation Technique in the Treatment of Complex Brain Arteriovenous Malformations (HOTAVM)
Study on Benefits and Risks of Hybrid Operation in the Treatment of Complex Brain Arteriovenous Malformations
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shuo Wang, MD
- Phone Number: 861059976510
- Email: captain9858@vip.sina.com
Study Contact Backup
- Name: Jun Wu, MD
- Phone Number: 861059976510
- Email: wujunslf@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Recruiting
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Guilin Li, MD
- Phone Number: 861083198899
-
Beijing, Beijing, China, 100070
- Recruiting
- Beijing Tiantan Hospital Capital Medical University
-
Contact:
- Shuo Wang, MD
- Phone Number: 861059976510
- Email: captain9858@vip.sina.com
-
Contact:
- Jun Wu, MD
- Phone Number: 861059976510
- Email: wujunslf@126.com
-
Beijing, Beijing, China, 100088
- Recruiting
- General Hospital of Rocket Army
-
Contact:
- Weijian Jiang, MD
- Phone Number: 861066343337
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Recruiting
- Qilu Hospital, Shandong University
-
Contact:
- Donghai Wang, MD
- Phone Number: 8653182166173
-
Qingdao, Shandong, China, 266034
- Recruiting
- Qingdao Municipal Hospital
-
Contact:
- Chuanfeng Li, MD
- Phone Number: 8653282789017
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Recruiting
- Huashan Hospital, Fudan University
-
Contact:
- Liang Chen, MD
- Phone Number: 860215288999
- Email: chenlianghs@126.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- Gao Chen, MD
- Phone Number: 8657187783777
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients of all ages;
- diagnosed with arteriovenous malformations (AVMs) in brain parenchyma (including cerebrum and cerebellum) by DSA, with/without dura arteriovenous fistula;
- with any operative indications as follows: (1) with stable hematoma or history of hemorrhage due to bAVMs, and allowed selective operation; (2) with recurrent epilepsy seizure, having failed treatment with antiepileptic drugs (AEDs); (3) with induced deterioration of neurological functions;
- with Spetzler-Martin Grades from I to IV;
- who provide informed consent.
Exclusion Criteria:
- >70 years old with no significant hemorrhagic risk of bAVMs;
- with Spetzler-Martin Grade ≥V;
- accompanied by severe chronic disease, organ dysfunction, or malignant tumor that cannot tolerate the operation;
- allergic to iodinated contrast agent;
- unable to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Traditional microsurgery group
Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater.
No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed.
The DSA will be performed in 3 days after the operation.
|
The classical mode of operations in neurosurgery.
The operation is performed with neurosurgical instruments and microscope.
Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on.
But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
|
|
Experimental: Hybrid operation group
Patients receive microsurgical operation under the assistance of intraoperative DSA, endovascular embolization and/or balloon occlusion in the one-staged hybrid operating theater.
|
An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools.
All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
neural function deterioration
Time Frame: 3 months after operation
|
Increasing of mRS and mRS>2
|
3 months after operation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
neural function deterioration in 6 months
Time Frame: 6 months after operation
|
Increasing of mRS and mRS>2
|
6 months after operation
|
|
neural function deterioration in 12 months
Time Frame: 12 months after operation
|
Increasing of mRS and mRS>2
|
12 months after operation
|
|
postoperative mortality
Time Frame: 7 days after operation
|
the fatality due to operation
|
7 days after operation
|
|
operation-related complications
Time Frame: 7 days after operation
|
any complications that occur within 7 days from the date of operation, including intracranial hemorrhage or infarction, infection of the central nervous system, infection of the respiratory system, cranial nerve deficits, and other symptomatic complications
|
7 days after operation
|
|
postoperative bAVMs residue
Time Frame: 7 days after operation
|
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
|
7 days after operation
|
|
3 months bAVMs residue
Time Frame: 3 months after operation
|
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
|
3 months after operation
|
|
6 months bAVMs residue
Time Frame: 6 months after operation
|
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
|
6 months after operation
|
|
12 months bAVMs residue
Time Frame: 12 months after operation
|
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
|
12 months after operation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shuo Wang, MD, Beijing Tiantan Hospital
Publications and helpful links
General Publications
- Wang M, Qiu H, Cao Y, Wang S, Zhao J. One-staged in situ embolization combined with surgical resection for eloquence protection of AVM: technical note. Neurosurg Rev. 2019 Sep;42(3):783-790. doi: 10.1007/s10143-019-01137-w. Epub 2019 Jul 30.
- Wang M, Jiao Y, Cao Y, Wang S, Zhao J. Surgical management of complex brain arteriovenous malformations with hybrid operating technique: study protocol of a prospective registry and a pragmatic clinical trial. BMC Neurol. 2019 Apr 30;19(1):75. doi: 10.1186/s12883-019-1289-3.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Cardiovascular Abnormalities
- Neoplasms, Vascular Tissue
- Vascular Malformations
- Congenital Abnormalities
- Hemangioma
- Arteriovenous Malformations
- Cerebrovascular Disorders
Other Study ID Numbers
Other Study ID Numbers
- BJTTH-007
- 2016YFC1301801 (Other Grant/Funding Number: National Key Technologies R&D Program of China)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.